This document discusses hepatocellular carcinoma and treatment with sorafenib. It summarizes a clinical trial that found sorafenib prolonged overall survival compared to placebo in patients with advanced hepatocellular carcinoma. The median overall survival was 46 weeks for sorafenib versus 34 weeks for placebo, representing a 44% increase in survival time. Sorafenib also prolonged time to progression compared to placebo. Based on these results, sorafenib became the first systemic therapy to prolong survival for hepatocellular carcinoma patients.